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The mitochondrial nicotinamide nucleotide transhydrogenase (NNT) uses the protonmotive force to transfer
electrons from NADH to NADP, thereby maintaining the NADP/NADPH pool reduced to protect mitochondria
from oxidative damage. In this issue, Nickel et al. (2015) show that NNT also operates in reverse, oxidizing the
NADP/NADPH pool, thereby disrupting antioxidant defense.The way we have been taught inevitably
influences how we think of metabolic pro-
cesses—I always remember the Krebs
cycle as a complete circle that only
goes clockwise! Of course, the textbook
presentation is just a way of compiling
information concisely, and in vivo meta-
bolic networks can be quite different.
Similar simplifications affect our view of
mitochondrial proton translocating com-
plexes. A good example is the FoF1-ATP
synthase that utilizes the protonmotive
force across the inner membrane to drive
ATP synthesis during oxidative phosphor-
ylation. However, if the protonmotive
force is too low then the protein can turn
into an ATPase, hydrolysing ATP and
pumping protons out of the mitochondria.
This occurs in vivo, for example during
ischemia when respiration is prevented,
thereby draining away the ATP syn-
thesized by glycolysis (St-Pierre et al.,
2000). Mitochondrial respiratory com-
plexes can also be driven ‘‘backwards,’’
compared to their conventional direction,
depending on the balance of thermody-
namic forces. For example, a recent studyto which I contributed suggested that
complexes I and II may operate in reverse
and contribute to ischemia-reperfusion
injury (Chouchani et al., 2014). During
ischemia, complex II utilizes the reduced
Coenzyme Q pool to convert fumarate to
succinate, then upon reperfusion the
accumulated succinate drives reversal of
complex I, thereby producing damaging
reactive oxygen species (ROS) (Chou-
chani et al., 2014).
More interesting than the reversal of
respiratory complexes in pathology is
the possibility that such unconventional
operation may occur in normal physi-
ology. For example, the reversal of com-
plex II during anoxia may generate succi-
nate as a hypoxic signal, complex I going
backward could be a physiological ROS
signal, and ATP hydrolysis by the FoF1-
ATP synthase might enable maintenance
of a protonmotive force independently of
the respiratory chain (Brown et al., 2006;
Chouchani et al., 2014).
In this issue, Nickel et al. show that
the latest proton pumping mitochondrial
complex that may operate in two direc-tions is the nicotinamide nucleotide trans-
hydrogenase (NNT) (Nickel et al., 2015).
The NNT is a mitochondrial inner mem-
brane protein that takes electrons from
NADH to reduce NADP to NADPH, utiliz-
ing the protonmotive force across the
inner membrane to drive the process
(Figure 1A). This coupling of electron
transfer to the protonmotive force is
essential to maintain the difference in
redox state between the mitochondrial
NADP/NADPH and NAD/NADH pools,
despite their identical midpoint potentials
(Rydstro¨m, 2006). This redox difference
is essential for the quite different biolog-
ical roles of the two nicotinamide nucleo-
tides. The NAD/NADH pool mainly acts
a conduit for electrons from substrates
to the respiratory chain and is thus
only partially reduced (Eh  300 mV).
In contrast, the mitochondrial NADP/
NADPH pool supplies electrons to
glutathione reductase, to maintain the
mitochondrial glutathione/glutathione di-
sulfide ratio high, and to thioredoxin
reductase 2, which keeps the matrix thio-
redoxin 2 pool reduced (Murphy, 2012).eptember 1, 2015 ª2015 Elsevier Inc. 363
Figure 1. The Nicotinamide Nucleotide Transhydrogenase of the Mitochondrial Inner
Membrane in Forward and Reverse Modes
(A and B) The nicotinamide nucleotide transhydrogenase (NNT) couples electron movement between the
NADP/NADPH and NAD/NADH pools to the protonmotive force (Dp) across the mitochondrial inner mem-
brane. In (A), the NNT operates in its conventional forward mode, using the protonmotive force to move
electrons from NADH to NADP and thereby maintain the NADP/NADPH pool reduced. This in turn enables
the activity of glutathione reductase and thioredoxin reductase 2 to decrease mitochondrial oxidative
damage. In (B), the NNT is operating in reverse mode, taking electrons from NADPH to NAD to maintain
oxidative phosphorylation. This disrupts antioxidant defenses and increases oxidative damage. The struc-
ture of the NNT is based on PDB 409U of the dimer of the protein from Thermus thermophilus.
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NADPH pool is far more reduced
(Eh415mV) than the NAD/NADH pool.
The only known role for the NNT is to
use the protonmotive force to help main-
tain the redox difference between mito-
chondrial NADP/NADPH and NAD/NADH
(Figure 1A). While the NADP-dependent
isocitrate dehydrogenase and malic
enzyme also contribute, this function of
NNT is important, as is illustrated by a
C57BL/6 mouse strain (6J) that has an
inactive NNT (Freeman et al., 2006; Toye
et al., 2005). The 6J strain has increased364 Cell Metabolism 22, September 1, 2015 ªoxidative damage and disrupted insulin
signaling when compared to a control
strain (6N) with a functional NNT (Freeman
et al., 2006; Toye et al., 2005). This view of
the NNT has now been extended by the
fascinating work of Nickel et al. (2015),
who suggest that under some conditions
the NNT can act in reverse, passing elec-
trons from NADPH to NAD while pumping
protons out of the mitochondrial matrix
(Figure 1B).
This hypothesis arose from studying a
model of heart failure, which unexpect-
edly showed that mice lacking NNT had2015 Elsevier Inc.less oxidative damage to the heart than
controls with an active NNT. This was sur-
prising, given the role of NNT in protecting
against oxidative damage: how could in-
activating the NNT decrease oxidative
damage? The authors hypothesized that
the stress to the heart in this model was
causing the NNT to run backward, suck-
ing electrons from NADPH and feeding
them into the NAD/NADH pool so as to
maintain oxidative phosphorylation. This
oxidation of the NADP/NADPH pool in
turn undermined antioxidant defense by
the glutathione and thioredoxin systems,
leading to oxidative damage (Figure 1B).
In the mouse strains lacking NNT, this
reversal could not occur, the NADP/
NADPH pool was maintained, and they
had less oxidative damage than the con-
trols with an active NNT.
This elegant model was shown to be
plausible in vitro, but of course just
because a process can occur in vitro
doesnotmean that itwill takeplace in vivo.
My view is that the evidence presented for
NNT reversal contributing to oxidative
damage in vivo is strong, but not yet defin-
itive. Further work will be necessary to
explore this intriguing hypothesis. For
example, one limitation is that the in vivo
data are based on comparison of two
mouse strains; future studies on mice
where NNT is conditionally deleted are
required to further test this hypothesis,
as is acknowledged by the authors.
This work does introduce the fasci-
nating possibility that the NNT can be
reversed from its ‘‘normal’’ direction
in vivo under pathological conditions.
Could there also be a physiological role
for NNT reversal? One possibility is that
by altering the NADP/NADPH ratio, and
thus the activity of the glutathione and thi-
oredoxin systems, the activity of thiol-
dependent enzymes in the matrix could
be modulated, adding a further nuance
to redox regulation. Another idea worth
exploring is that the NNT provides a link
between the NADP/NADPH and NAD/
NADH pools, and the protonmotive force,
thereby potentially coordinating changes
in these key determinants of mitochon-
drial activity (Gameiro et al., 2013). Finally,
this stimulating study reminds us that the
direction of biochemical reactions in vivo
is determined by local thermodynamics,
not textbooks, potentially providing fresh
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A low level of cardiomyocyte turnover occurs in the adult mammalian heart, but the source of these new cells
remains unknown. Kimura et al., 2015 utilized a novel hypoxia-induced fate mapping system to identify a rare
population of adult cardiomyocytes undergoing cell-cycle entry and expansion in healthy adult hearts and
following ischemic injury.Anestablishedparadigm incardiovascular
regenerative medicine is that adult
mammalian cardiomyocytes have limited
proliferative capacity (Laflamme and
Murry, 2011). By examining the proportion
of carbon-14 integrated into cardiomyo-
cyte DNA from adults born during the nu-
clear testing era in the 1950s, Bergmann
et al. (2009) estimated that cardiomyocyte
turnover rate in humans declines with age
from 2% per year in the first decade of
life to less than 1%per year by the seventh
decade. Thus, the vast majority of adult
mammaliancardiomyocytesare terminally
differentiatedandunable to reenter thecell
cycle to replace cells lost during myocar-
dial injury (Figure 1). This is in contrast to
the remarkable cardiac regenerative po-
tential exhibited by lower vertebrates
such as zebrafish, as well as the lesser
regenerative capacity of the neonatal
mammalian heart (Porrello et al., 2011;
Poss et al., 2002; Sturzu et al., 2015). The
low cardiomyocyte turnover described by
Bergmann et al. (2009) suggests that asmall population of proliferative cells may
be present in the adult heart; however,
the identity of these cells (e.g., progeni-
tors, immature cardiomyocytes/cardio-
myoblasts, or specialized cardiomyocytes
with proliferative potential) remains
elusive. In a recent study, Kimura et al.
(2015) reported that rare adult proliferative
cardiomyocytes are enrichedwithin a hyp-
oxic environment and can expand in the
presence of myocardial ischemic injury.
In order to search for this rare popula-
tion of proliferating myocytes, Kimura
et al. (2015) devised a novel system to
track hypoxic cells. In an earlier study,
the authors found that high oxygen levels
may be responsible for the cell-cycle ar-
rest observed in adult mammalian cardio-
myocytes (Kimura et al., 2015; Puente
et al., 2014). Thus, by logical exten-
sion, a hypoxic environment may induce
greater cardiomyocyte proliferation as
seen in an actively dividing fetal heart. In
this study, an elegant CreER-LoxP mouse
model was utilized to label hypoxic cardi-omyocytes expressing Hif-1a, a master
regulator of the hypoxic stress response.
Specifically, the CreER recombinase
was fused to the oxygen-dependent
degradation (ODD) domain of Hif-1a,
restricting CreER activity to hypoxic con-
ditions. Thus, when driven by either a
ubiquitous CAG promoter or a cardio-
myocyte-specific a-myosin heavy chain
promoter, this CreER-ODD construct
fluorescently labeled hypoxic cardiomyo-
cytes in adult mice carrying a ROSA26-
flox-stop-flox-tdTomato cassette. The
authors confirmed that the Cre-labeled
cardiomyocytes are hypoxic by showing
the co-localization of the hypoxia detector
pimonidazole with tdTomato+ cardio-
myocytes. When these mice were sub-
jected to global hypoxia and then injected
with tamoxifen to activate CreER-medi-
ated recombination, the authors saw
a significant increase in tdTomato+
cardiomyocytes throughout the heart,
suggesting that the CreER-ODD system
can accurately label hypoxic cells.eptember 1, 2015 ª2015 Elsevier Inc. 365
